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Developing Anti-CD30 Recombinant Immunotoxins Targeting Shed and 
non-Slied Epitopes for Cancer Therapy 
Abhishek Sinha, Richard Beers, Satoslii Nagata, Tapan Bera, Masanori Onda, Kenneth Santora, Ira 
Pastan. Laboratory of Molecular Biology, National Cancer Institute, National Institute of Health, 
Bethesda, MD 20892. (Sponsored by Vincent DeVita, Yale Cancer Center, Yale University School 
of Medicine). 
Although combination chemotherapy and radiation therapy achieves high remission rates in patients 
with Hodgkin's disease (HD) and some forms of Anaplastic Large Cell Lymphoma (ALCL), most 
patients who relapse will die of their disease. Also, approximately 20% of long term survivors of 
HD who receive chemotherapy and radiation therapy develop secondary malignancies, which further 
underlines the need for more selective therapeutic agents. CD30, a 120 kd transmembrane protein of 
the TNF receptor family, is a human lymphocyte activation antigen that is consistently over¬ 
expressed in Reed Sternberg cells (HD) and in ALCL cells, yet it is poorly expressed on normal 
lymphocytes, making it an ideal target for selective immunotherapy. Recombinant immunotoxins 
(RITs) genetically fuse the Fv (variable region) of a monoclonal antibody (MAb) targeting a surface 
tumor antigen with a modified form of the Pseudomonas exotoxin, combining the specificity of an 
antibody with the powerful cytotoxicity of a bacterial toxin. To develop anti-CD30 RITs, four new 
high affinity anti-CD30 antibodies (T420, T427, T405, T105) targeting different epitope groups were 
selected from a panel of anti-CD30 MAbs. Because part of CD30 is cleaved into a soluble fragment, 
it is important to design RITs that target the shed and non-shed CD30 epitopes. After cloning and 
sequencing the variable regions of these MAbs, separate expression constructs were made for the 
light chains (Vl) and the heavy chains fused to the Pseudomonas exotoxin (VH + PE38). After 
expressing, refolding, and purifying the RITs, each RIT’s specific cytotoxicity was evaluated in 
various CD30+ cell lines. Three of RITs demonstrated high degrees of specific cytotoxicity towards 
CD30+ cells in in vitro assays, with IC5o’s as low as 0.63 to 2.0 ng/ml. RITs with the highest 
activities will be further characterized, and the RIT with the most favorable properties may be a 
candidate for development for clinical trials. 
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Combination chemotherapy and radiation therapy can cure a substantial fraction of 
patients with Hodgkin’s Disease (HD) (1). In the advanced stages of the disease, 
approximately 30 to 50% of patients will respond to therapy but relapse and die of this 
disease (2). Overall, 20% of patients with Hodgkin's disease die as a result of their illness 
(3). In addition, conventional therapy for Hodgkin’s disease leads to several co-morbidities. 
Long-term survivors of Hodgkin’s Disease who received chemotherapy and radiotherapy 
have a higher risk of developing a secondary malignancy. The possible secondary 
malignancies include myelodysplastic syndromes, AML, lung cancer, NHL, breast cancer, 
gastric cancer, sarcoma, and malignant melanoma (4). Women who are treated with 
radiation therapy to the chest during adolescence are especially at risk for developing breast 
cancer (5). Approximately 19% of long term survivors of Hodgkin’s disease receiving 
chemotherapy and radiotherapy will develop a secondary malignancy after 15 years from 
their treatment. Other complications of radiotherapy include pulmonary fibrosis and 
accelerated atherosclerosis. The poor prognosis in patients who relapse and the co¬ 
morbidities of patients receiving combinational chemotherapy and radiotherapy underlie the 
need for more selective therapy in Hodgkin’s Disease. 
Anaplastic large cell lymphoma (ALCL), a novel category of lymphoma (categorized 
in 1985) that has a cohesive proliferation of large pleomorphic blastic cells and consistently 
expresses the cytokine receptor CD30, can be clinically divided into a primary systemic 
form, a primary cutaneous form, and a secondary form (6,7). The most common subform is 
the primary systemic form which can account for 2 to 8% of non-Hodgkin’s lymphomas in 
adults and about 20-30% of large cell lymphomas in children (7). It is worth noting that 
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because ALCL has been recognized relatively recently and in the past has been misdiagnosed 
(as malignant histiocytic tumors, regressing atypical histiocytosis, melanoma, metastatic 
carcinoma), its true prevalence is unknown. The primary systemic form can also be divided 
into groups that are anaplastic lymphoma kinase (ALK) positive or negative. Anaplastic 
lymphoma kinase is a receptor tyrosine kinase. The ALK+ ALCL form presents mostly in 
the first three decades of life while the ALK- form occurs in older patients (8,9,10). 
Extranodal involvement is possible in both ALK+ and ALK- subforms (esp. ALK+) and 
includes skin, bone, soft tissue, lung, liver, and CNS (rare) (11). The prognosis of primary 
ALCL can also vary depending on the presence of ALK. The 5 year overall survival for 
ALK+ ALCL is 71% +/- 6% and for ALK- ALCL is 15% +/- 11% (11). The secondary form 
of ALCL arises from the progression of other lymphomas and is associated with a poor 
prognosis. While the prognosis of ALCL varies depending on the subforms, there is a 
clinical need, as in HD, for more selective therapies. 
Hodgkin’s disease and ALCL are distinct clinical entities, but they share many 
characteristics. One of the most important of these is that both Reed-Sternberg cells of HD 
and ALCL cells consistently expresses CD30, a human lymphocyte activation marker. 
CD30, a type 1 transmembrane glycosylated protein of 120/105 kDa, is a member of the TNF 
receptor (TNFR) superfamily (12,13). CD30 expression in normal cells is restricted to 
activated lymphocytes and is absent from hematopoietic stem cells. Stimulation of CD30 has 
been associated with a variety of biological activities in lymphoid cells (depending on the 
circumstances) including proliferation, activation, differentiation, and cell death (14). It is 
also known that CD30 cross-linking leads to NF-k B activation (15,16). NF-k B activation 
(via CD30) is believed to transcriptionally regulate several cellular genes (including various 
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cytokines) which may explain some of the numerous biological effects of CD30 activation, 
such as lymphocyte proliferation (17). The extracellular portion of CD30 can also be 
cleaved by a zinc-metalloprotease to yield a soluble form (sCD30, mass 85/90 kDa) (18). 
Increased levels of sCD30 have been found in patients with HD and ALCL and correlate 
with disease burden. In fact, the median sCD30 levels in patient with HD and ALCL were 
found to be 20 to 1500 times greater than in normal controls (19). Because CD30 expression 
is restricted to Reed-Sternberg cells, ALCL cells, and some activated lymphocytes and is 
absent from hematopoietic stem cells, it is an excellent target for selective immunotherapy. 
One possible strategy for targeting CD30 is the use of recombinant immunotoxins 
(RITs). RITs are chimeric proteins that genetically fuse the Fv (fragment of the variable 
region) of a monoclonal antibody (MAb) that targets a tumor surface antigen with a modified 
bacterial toxin (or plant toxin) (20,21). Hence, RITs combine the specificity of a MAb with 
the powerful cytoxicity of a bacterial toxin (Figure 1). RITs are useful in cases when 
unarmed MAbs are not able to kill cancer cells, which is often the case. Linking a MAb or 
Fv of MAb with a toxin (as opposed to cytotoxic drug or radioisotope) has many advantages 
which include: 1. toxins are highly potent, 2. toxins are not mutagenic, 3. toxins are not toxic 
to bone marrow, 4. toxins can kill cancer cells that are chemotherapy resistant, 5. It is rare 
for cells to develop resistance to bacterial toxins. There are several generations and forms of 
immunotoxins (ITs). The term recombinant immunotoxin is used to signify that the toxin 
and Fv of the MAb were genetically fused rather than chemically conjugated. The RITs 
utilize a modified Pseudomonas exotoxin which kill cells by ADP ribosylating and 
inactivating elongation factor 2 (Figure la) (20). The RIT binds to its target and enters the 
cell through an endocytosis pathway. The Pseudomonas exotoxin is proteolytically cleaved 
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and a portion of it is sent to the Golgi and then the endoplasmic reticulum, from where it is 
translocated to the cytosol. Once in the cytosol, the toxin kills the cell by inhibiting protein 
synthesis. Clinical trials with other RITs that target other tumor antigens indicate that such 
therapy may be effective in hematologic malignancies. LMB-2 (anti-CD25 scFv 
immunotoxin) resulted in significant clinical responses in various types of leukemia and 
lymphoma (22). In addition, RFB4 (dsFv)-PE38 (the anti-CD22 RIT) was able to achieve 
high rates of complete remission in patients with Flairy Cell Leukemia refractory to 
chemotherapy (23,24). 
A number of attempts to target CD30 with MAbs and immunotoxins have been made. 
Some of the earlier MAbs generated to target CD30 are Ber-H2, HeFi-1, M44, M67, and Ki- 
1 (25). Anti-CD30 MAbs have been shown to induce cell growth inhibition and apoptosis in 
ALCL (26,27). Mouse models using ALCL xenografts that were treated with the HeFi-1 
MAb and the M44 MAb had growth arrests of tumors and increased in survival (27,28). 
Clinical studies with the Ber-H2 MAb and the HeFi-1 MAb were performed. The Ber-H2 
MAb was given to patients (along with a small amount of 1 ’'l-labeled Ber-H2) to patients 
with refractory Hodgkin’s disease. Tumor localization was seen (through radioimaging) in 
50% of the tumors, and there was non-specific uptake in the spleen and liver. This study 
revealed no clinical responses or toxicities. Results of the study with HeFi-1 MAb revealed 
tumor localization and no responses (25). Recently, a group reports some efficacy of another 
MAb (SGN-30) on HD in in vitro studies and in murine models (29). Immunotoxins 
targeting CD30 have had some effects in in vitro studies and animal models. A RIT that was 
derived from the Ki-4 MAb and modified Pseudomonas exotoxin was shown to have some 
specific cytotoxicity in in vitro studies with CD30+ cells and some anti-tumor activity in a 

SCID mouse model (30,31). Clinical studies with a Ber-H2 MAb conjugated to a saporin 
toxin used in patients with HD revealed greater than 50% reduction in tumor mass, but these 
responses were temporary (32). Recently, a Phase I study with Anti-CD30 Ricin A-Chain 
immunotoxin (Ki-4.dgA) had minor clinical responses (1 partial remission in 15 patients) but 
significant toxicity (33). The Pastan lab has also made several RITs which have shown 
significant specific activity in both in vitro studies and animal models (34,35). 
Statement of purpose and hypothesis: 
While previous attempts to target CD30 with MAbs and ITs have shown some efficacy in in 
vitro assays and in animal models, producing a RIT with improved properties should result in 
greater clinical efficacy. Four MAbs (T420, T427, T105, and T405) were selected from a 
panel of anti-CD30 MAbs recently produced and characterized by affinity assays and CD30 
epitope mapping (Figure 2, Table 1). Because a high affinity parent MAb should produce a 
more active RIT, two of the MAbs (T420 & T427) were selected because of their very high 
affinities (T420's Kd = 1.9 nM, T427’s Kd = 0.9 nM) towards CD30. The epitope the RIT 
targets may be especially significant because, as mentioned above, the extracellular portion 
of CD30 is cleaved to yield a soluble fraction (sCD30), and sCD30 levels can be dramatically 
higher in patients with HD and ALCL. CD30 has multiple epitope groups, some of which 
are located on the non-shed portion (S. Nagata, unpublished data. Figure 2). The advantage 
of a RIT that targets a non-shed epitope is that it should have a greater number of available 
binding sites and should not be neutralized by sCD30. RITs based on T105 and T405 parent 




Cloning of Vh (variable region of the heavy ehain) and VL (variable region of the light 
chain) of the Parent MAbs. 
In order to clone the Vh and VL of the four parent MAbs (T420, T427, T105, T405), the total 
cellular RNA was extracted from hybridoma cells and used to produce the Vh and Vl cDNA 
through a SMART RACE (Rapid Amplification of cDNA Ends) reaction. The Vh and Vl 
cDNA were then separately cloned into a pCR2.1 -TOPO (plasmid) vector. Isolation of total 
cellular RNA from 107 hybridoma cells was done with an RNA extraction kit (StrataPrep 
Total RNA Miniprep Kit, Stratagene Cloning Systems, Ea Jolla, CA). From each hybridoma 
total RNA, the cDNA of the Vh and VL of the MAbs (T420, T427, T105, T405) were 
generated using SMART RACE cDNA Amplification Kit (Clontech, Palo Alto, CA). 
Essentially a two step process, the first part involved generating adaptor-ligated cDNA 
through a reverse transcriptase reaction of 5ug RNA using a 3’ primer that was derived 
from the sequence of the constant region (Chi or Cl) or hinge region (for heavy chains only) 
for that parent MAb. Since different subclasses of immunoglobulins have different constant 
region sequences, the 3” primers were designed and chosen corresponding subclass of the 
parent MAb using the Kabat database (Table 1). The 3’ primers used were: yl (hinge region 
primer, T105 VH ) = ACC-ACA-ATC-CCT-GGG-CAC-AAT-TTT-CT; y2a (hinge region 
primer, T427 VH) = TCT GGG CTC AAT TTT CTT GTC CAC C; y2b (hinge region 
primer, T420 & T405 VH) = GCT GGG CTC AAG TTT TTT GTC CAC C; k (for all VL) = 
CTC ATT CTT GTT GAA GCT CTT GAC ATT. The next step involved using the cDNA 
generated from the reverse transcriptase reaction as a template for a 5’ RACE reaction. This 
reaction used a 5' end primer that binds to the adaptor sequence and a 3’ end primer also 
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derived from the constant region of the appropriate immunoglobulin subclass (but is 
upstream to the primers used in the first step). These 3' primers for the RACE reaction were: 
yl (CHI primer, T105 VH) = CAG GGT CAC CAT GGA GTT AGT TTG, y2a (CHI region 
primer, T427 VH) = TAG AGT CAC CGA GGA GCC AGT TGT, y2b (CHI region primer, 
T420 & T405 VH) = TCC AGA GTT CCA AGT CAC AGT CAC, k (for all VL) = GAC 
TGA GGC ACC TCC AGA TGT TAA. To purify the products of the 5’ RACE reaction, the 
PCR products were run on 1.2% low melting agarose gel, and bands of the expected product 
size were excised and purified with Qiaquick gel extraction kit. Using Invitrogen’s TOPO 
TA cloning kit (Invitrogen, San Diego, CA), these purified PCR products were cloned into a 
pCR2.1 -TOPO vector. These clones were then sequenced. To eliminate the possibility that 
the clone contained a PCR generated error, at least five clones per VfI or VL clone were 
sequenced. Once the sequences were obtained, they were aligned according to the Kabal 
alignment scheme (36). 
Construction of Plasmids for dsFv-PE38 (disulfide-stabilized Fv fragment linked to a 
modified Pseudomonas exotoxin) Recombinant Immunotoxins. 
After cloning and sequencing the Vh and VL of the parent MAb, cysteine (cys) mutations 
were introduced into the Vh and VL (to form a disulfide bond during the refolding process), 
and the Vh w/cysteine and Vl w/cysteine were incorporated into separate plasmid 
expression vectors. In the Vh expression vector, VH w/cys is joined to a modified 
Pseudomonas exotoxin that is 38 kDa large (PE38). A cysteine mutation was introduced into 
the Vl chain at position 100 (according to Rabat numbering) in framework region 4 (FR4) 
and into the Vh chain at position 44 in framework region 2 (FR2) (Figure 3a) (37). To 

introduce a cysteine mutation in VL and prepare it for ligation into the expression construct, 
the VL chain was PCR amplified with a 5’ primer (that introduce an Nde I site) and a 3’ 
primer that introduced a cysteine mutation in position 100 (FR4) and an EcoRl site. Because 
a cysteine mutation had to be introduced in the middle (position 44) of the Vh chain, a 
splicing overlap extension PCR method was employed (38). This involves PCR amplifying 
the first half of the Vh chain with primers that introduce a Nde I site (with an ATG initiation 
codon) at the 5’ end and a cysteine mutation (at position 44) at the 3’ end of the fragment. 
The second fragment of Vh is produced by PCR amplification with primers that introduce a 
cysteine mutation at position 44 in the 5’ end of the fragment and a Hind III mutation at the 
3’ end. Because Vh fragment 1 and fragment 2 overlap (around the cysteine mutation), an 
overlap reaction produces a Vh w/cysteine chain by allowing the overlapping ends to anneal 
and extend. This full length Vh segment with cysteine is amplified with the 5' and 3’ 
primers. The V^cys) and Vn(cys) were digested with Nde I and EcoRl (for Vl) or Hind III 
(for Vh). They were then ligated into separate T7-based expression vector pRB98a (which 
originated from pUL17; 4) (Figure 3b). The Vh expression vector attaches Vh (cys) to PE38 
(with a small connector region in between) (Figure 3c). The VL(cys) is alone in a separate 
expression vector (Figure 3d). The sequence of the VH(cys)-PE38 and V^cys) expression 
vector were verified. 
Production and Purification of dsFv Recombinant Immunotoxins (RITs) 
The preparation of recombinant dsFv immunotoxins involved expressing the Vh (cys)-PE38 
and Vl (cys) (which collect as intracellular inclusion bodies, IB), purifying, solubilizing 
and denaturing the IB, refolding the IB in a redox-shuffling buffer, a dialysis process, and 
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column chromatography to separate the refolded dsFv IT from aggregates (39,40). The 
VH(cys)-PE38 and VL(cys) expression vectors were separately transfected into E.coli BL21 
(>J)E3). Protein expression was induced in the bacterial cultures with ImM isopropyl-1- 
thio-[3-D-galactopyranoside for 2 hrs during the exponential growth phase. The cells were 
collected by centrifugation. The recombinant proteins, which collect as intracellular 
inclusion bodies, were recovered by lysing the cells. The inclusion bodies were then 
washed repeatedly with a non-ionic detergent. After washing, the purified inclusion bodies 
are solubilized and denatured with 6 M guanidine hydrochloride and then reduced by 
dithioerthritol for approximately 5 hours. After being solubilized and reduced, Vn(cys)- 
PE38 and VT(cys) were added in a 2:1 molar ratio and diluted (lOOx) into a redox-shuffling 
buffer which contains oxidized and reduced glutathione and L-arginine (to help prevent 
protein aggregation). The refolding process (which takes about 38 to 42 hrs) is followed by 
dialysis against a Tris buffer (with 0.1 M urea) for approximately 18 hours to remove the 
guanidine hydrochloride. The refolded, dsFv RIT is then separated from misfolded 
aggregates and bacterial protein through a series of anion exchange chromatography (Q- 
Sepharose and then Mono-Q [Amersham Pharmacia Biotech]) and then size exclusion 
chromatography (TSK3000; TOSOOH, Tokyo, Japan). The refolded dsFv was further 
analyzed by SDS-Page gel for size and purity. A Bradford assay (Coomassie Plus, Pierce, 
Rockford, IL) using a BSA standard was used to measure the concentration of the 
recovered IT. 
Cell Lines for Cytotoxicity Assays. 
The cell lines used for the cytotoxicity assay include Atac-4 and A431-CD30 (which is a 
stable transformant of A431 that expresses CD30) (41,42). A431 is a human epidermoid 
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cell line, and Atac-4 is a stable transformant of A431 that expresses CD25 (but is CD30-). 
ALCL-derived cell lines were SUDHL-1 and KARPAS-299 (from the German Collection of 
Microorganism and Cell Cultures, DSMZ. Braunschweig, Germany). L540 was a HD 
derived cell line (from Dr. C.S. Duckett, NIH. Bethesda, MD). SUDHL-1, KARPAS-299, 
and L540 cells are all CD30+. Iscove’s modified Dulbecco’s medium (Life Technologies, 
Inc., Gaithersburg, MD) was used for culturing the cells. 
In Vitro Cytotoxicity Assay 
Activity of the RIT is measured by the inhibition of cellular protein synthesis as measured 
by 'H-leucine incorporation (41). Cells are plated in a 96 well plate at 2.0 x 104 cells/well. 
They are then incubated for 24 hrs if the cell line is attached or for 1 hrs if the cells grow in 
suspension. Serial dilutions of the RIT are made in PBS with 0.2% with human serum 
albumin. The RIT are added to the cells (3 wells for each RIT dilution) and then incubated 
for 18-30hrs (the incubation period varies depending on the growth rate of the cell line being 
tested). After being incubated with the RIT, 2 pCi of 'II Leucine (diluted 1:10 in 0.2% HSA 
in PBS) is added and incubated with the cells for 2 to 5 hrs. If the cell line used is attached, 
the plates are frozen and thawed (to disattach the cells from the surface of the 96 well plate). 
If the cell line grows in suspension, the freezing and thawing step is not necessary. They are 
then harvested onto glass filters using a cell harverster (Tomtec, Hamden, CT). The 
incorporation of radioactivity (counts) is measured by an automated scintillation counter 
(1205 Beta-plate; Wallac, Gaithersburg, MD). 
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Surface Plasmon Resonance Assay 
A BIAcore (Biacore, Piscataway, NJ) biosensor was used to measure the affinity of the dsFv 
RIT for CD30. To measure the on and off rates, CD30-Fc (4000 resonance units) was 
affixed to a biosensor chip, and 25pg/ml of an Fr (in PBS) was injected over the chip 
surface for 5min . The RIT was then allowed to dissociate by flowing buffer over the chip. 
Binding kinetics were measured by using BIAevaluation 2.1 software (BIAcore). [The 
surface plasmon resonance assay was done largely by Richard Beers] 

RESULTS: 
Cloning of Vn (variable domain of the heavy chain) and Vl (variable region of the light 
chain) cDNA of the Parent MAb 
The cDNA of the Vh and V| domains of each of the MAbs (T420, T427, T105, T405) were 
cloned as described in “Materials and Methods”. The sequence data were arranged into 
tables organized by framework regions (FR) and complementary determining region (CDR) 
(Table 2 ). The amino acid sequences were also analyzed through an “Fv Sequence 
Alignment “ program (Molecular Modeling Section, Laboratory of Molecular Biology, 
NCI/NIH) that identifies any unusual residues in the framework region. This is important 
because unusual amino acids in the framework can prove to be problematic for the stability 
and activity of the Fv. One interesting anomaly among the Vh and Vl sequences was that 
CDR3 in the Vh chain for T405 has only three amino acid residues, considerably shorter 
than most other CDR3s. Otherwise, most of the cloned sequences appeared reasonable. 
Preparation and Purification of Anti-CD30 dsFv (disulfide-stabilized Fv) Iminunotoxin 
The dsFv RITs (recombinant iminunotoxin) were produced according to the protocol 
described in “Materials and Methods”. Cysteine mutations introduced into the VH-PE38 and 
VL chains allow them to form a disulfide bond during the refolding process (Figure la). The 
redox-shuffling buffer promotes the formation of the disulfide bond between Vh and V|. 
This disulfide form of IT was found to be more stable than the single chain form (Vh and Vl 
linked by a peptide) and has greater anti-tumor activity (37,39,43). 
Two important criteria for a successful RIT are yield and purity, as dsFv 
immunotoxins may aggregate during the refolding process (lowering yield and purity). A 
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low yield indicates that the Vh and VL are not stable in an Fv form. A dsFv RIT that cannot 
be recovered with good purity will likely have diminished activity because of the 
contaminants (misfolded protein aggregates). All four anti-CD30 dsFv RIT were made 
(T420, T427, T105, & T405) with reasonable yields (minimum acceptable yield is 1%, a 
yield >= 5% is desirable) ( Table 2). Also, all four were produced and recovered with high 
purity (Figure 4), indicating that their Fvs are relatively stable. Except for T420, the RITs 
are shown in reducing and non-reducing conditions. In non-reducing conditions, the 
disulfide bond is cleaved, causing Vh-PE38 to be separated from VL. Since good yields and 
high purity typically correlate with high activity, all four RITs appeared favorable at this 
stage. 
Testing Anti-CD30 RIT for Specific Activ ity 
The specific activity of the anti-CD30 dsFv RITs were measured by in vitro 
cytotoxicity assays in CD30+ cell lines. Because the Pseudomonas exotoxin’s mechanism 
of killing is through in ADP ribosylation of elongation factor 2, these cytotoxicity assays 
measure inhibition of cellular protein synthesis as means to determine the activity of the 
RIT. This inhibition of cellular protein synthesis correlates with cell death. The IC50 of the 
anti-CD30 dsFv was determined by applying varying concentrations of the RIT to 
A431/CD30 (see “Materials and Methods”). As a positive control, a potent anti-CD30 dsFv 
RIT previously made in the lab (T6 dsFv RIT) was included in the assay. To confirm that 
their cytotoxicity was specific, these anti-CD30 dsFv RIT’s were tested in a CD30 negative 
cell line, Atac4. 
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The results of the cytotoxicity assay indicate that T420 RIT, T105 RIT, and T427 
RIT were all highly active against CD30+ cells (with IC50 in the 0.63 ng/ml to 2.05 ng/ml 
range), whereas T405 RIT was not (IC50 > 100 ng/ml) (Figure 5a & b. Table 4a & b). In 
addition, 1405 RIT (which targets a non-shed epitope) was the most active, even more 
active than the potent control RIT T6. (Note that because of the space limitations on the 96 
well plate, it was not possible to test all four RITs and the T6 control in one plate. Hence, at 
least two assays were done for each cell line.) The cytotoxicity assay with the Atac4 cells 
(IC50 range 240 to 700 ng/ml) confirmed that the cytotoxicity was specific to CD30+ cells 
(Figure 5c & d. Table 4a & b). 
Cytotoxicity on HD and ALCL Derived Cell Lines 
The activity of T420 RIT, T427 RIT, T105 RIT, and T405 RIT was tested against a HD 
derived cell line (L540) and two ALCL derived cell lines (SUDHL-1 & Karpas 299). T6 
dsFv RIT was also used as a positive control in these assays. The results were qualitatively 
similar to those in the A431/CD30 assay. T420 RIT, T427 RIT, and T105 RIT all had high 
degrees of cytotoxicity towards the SUDHL-1 (IC50 range 7.4 ng/ml to 19 ng/ml) and 
Karpas 299 (IC50 range 17 ng/ml to 60 ng/ml) (Figure 6, Table 4a & b). The RITs were 
also active against L540 cells but to a lesser degree (IC50 60 ng/ml to 105 ng/ml). T405 RIT 
was not active against Karpas 299 and SUDHL-1 (IC50 > 100 ng/ml) and was not tested on 
the L540 cell line. Among all of these anti-CD30 dsFv RITs, T105 RIT which targets the 




Measuring the Affinity of the Anti-CD30 dsFv IT towards 0)30 
The affinities of the anti-CI)30 dsFv RITs towards CD30-Fc on a biosensor chip was 
measured by surface plasmon resonance assay (See “Materials and Methods'”). By 
measuring the on and off rates of the RIT binding to the CD30-Fc on the biosensor chip, the 
affinity was calculated (Kd). The Kd of T420 RIT, T427 RIT, T105 RIT, and T405 RIT 
were 5.8 x 10'8M, 3.6 x l(f8M, 1.2 x 1 O'8 M, and 3.14 x 10'7M (Table 5). The RIT with 
the highest affinity, T105, also had the highest activity against CD30 positive cells. 
Conversely, the RIT with the lowest affinity, T405, had the lowest activity against CD30 
cells. All of the RIT Fvs had lower affinities than the parent MAbs they were based on, 
which was not unexpected considering that MAbs are divalent and are generally in a more 
stable form. In addition, the parent MAb with the highest affinity, T427, did not have the 




While combination chemotherapy and radiation therapy can achieve high remission 
rates in Hodgkin’s Disease (1 ID), many of the patients who relapse will die from their 
disease (1,2,3). In addition, conventional therapy for Hodgkin’s disease leads to several co¬ 
morbidities, including the development of secondary malignancies. Anaplastic large cell 
lymphoma (ALCL) is a novel category of lymphoma that has a cohesive proliferation of 
large pleomorphic blastic cells and consistently expresses the cytokine receptor CD30 (6). 
While the prognosis of ALCL varies depending on the subforms, there is a clinical need, as 
in HD, for more selective therapies. 
HD and ALCL are clinically distinct, but they have many similarities. One of the 
most important of these similarities from the standpoint of designing a selective therapy is 
that both Reed-Sternberg cells (of Classic HD) and ALCL cells overexpress CD30. A 
number of attempts to target CD30 with MAbs and immunotoxins have been made. 
Although previous anti-CD30 RITs have demonstrated some effectiveness in in vitro assays 
and in animal models, a RIT with improved properties should have greater clinical efficacy. 
Two strategies were employed in attempting to develop an more effective RIT : 1) choosing 
parent MAbs with a high affinities to CD30 and 2) choosing parent MAbs that target epitopes 
in the non-shed portion of CD30. As mentioned in the introduction, CD30 is cleaved by a 
zinc-metalloprotease to produce a soluble fraction. CD30 also has multiple epitope groups, 
some of which are located on the non-shed portion of CD30 (Figure 2, S. Nagata - 
unpublished data). Targeting such epitopes has the advantage of: 1) having a greater number 
of binding sites available to the RIT and 2) not having the RIT neutralized by soluble CD30. 
Four novel anti-CD30 dsFv RITs (disulfide-stabilized Fv recombinant immunotoxins) were 
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produced based on two high affinity parent MAbs, T420 and T427, and two parent MAbs 
that target non-shed epitopes of CD30, T105 and T405. All four of the Fv’s from these 
MAbs had unique sequences. Three of these RITs (T420, T427, T105) had a high degree of 
activity against CD30+ cells. Among these, T105 R1T was consistently the most active 
against each CD30+ cell line. 
All four anti-CD30 dsFv RITs were produced with good yields (~5%). This is 
important for a number of reasons. Not all MAbs translate faithfully into an Fv form, so a 
good yield with high purity indicates stability of the Fv form. In addition, a good yield and 
high purity generally correlates with a highly active RIT. Another reason why yield and 
purity are important is that the best anti-CD30 dsFv RIT may be a candidate for clinical 
studies. Since producing RIT on a larger scale is a laborious and expensive process, it is 
important that the RIT can be produced with a reasonable yield. In addition, there are 
several strategies to improving the yield of a RIT which can be explored. One of these 
involves altering the conditions of the refolding process so that the RIT may aggregate less. 
Another approach is to use molecular modeling techniques to identify various framework 
residues which can be altered to produce an even more stable Fv configuration. 
The four anti-CD30 RITs were tested on a panel of CD30+ cells, including those 
derived from HD and ALCL. While they were some differences in how effective they were 
in each cell line, three (T420, T427, and T105) of the RITs were generally very active in all 
of the CD30+ cell lines. Among these, T105 RIT, which targets a non-shed CD30 epitope 
was consistently the most active. The surface plasmon resonance assay revealed that the 
T105 RIT Fv also had the highest affinity towards CD30 among the anti-CD30 RITs. Since 
previous studies with RITs indicate that the affinity of the Fv to its target is one of the most 
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important factors in determining activity, T105’s high activity may be explained by its high 
affinity to CD30 (35). Hence, it is unclear what the significance of T105 targeting a non¬ 
shed epitope is. Previous studies with anti-CD30 RITs did not find a relationship between 
RITs targeting different epitope groups within the shed region and their activity, but the 
non-shed region has not been explored before (35). As mentioned above, a RIT that targets 
a non-shed epitope should have several advantages. The idea that such a RIT should not be 
neutralized by soluble CD30 (sCD30) may be especially significant because it is believed 
that sCD30 may be dramatically elevated in a patient because it is shed in several places 
near a tumor site. However, it is difficult to replicate such conditions in an in vitro setting 
because the sCD30 released by the cells become quickly diluted by the media. It is also 
difficult to produce sCD30 in the quantities predicted in an in vivo setting and add it to an in 
vitro cytotoxicity assay to test the effects of neutralization of RITs that target shed epitope 
groups. Hence, it may only be possible of revealing the significance of targeting a non-shed 
epitope group through animal studies or through clinical studies. 
While T420 RIT and T427 RIT were also highly active in CD30+ cells, they were not 
as active as predicted considering the high affinity of their parent MAb. Again, not all MAb 
translate faithfully into an Fv form. This was confirmed by the surface plasmon resonance 
assay which revealed that both of these RITs’ Fvs had less affinity than their parent MAb. 
In addition, the lack of activity from the T405 RIT was surprising considering its good yield 
and high purity, which often correlate with strong activity. The surface plasmon resonance 
assay did reveal that the T405 RIT has significantly decreased affinity towards CD30, which 
may partially explain its low activity. Another interesting aspect of T405 RIT’s structure is 
that its CDR3 in VH has only three amino acids, which is considerably shorter than most 
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CDR3s in immunoglobulins (Table 3). CDR3 usually plays a critical role in binding, but it 
is unclear what the significance of this short CDR3 may play in T405 RIT’s lack of activity. 
Within the CD30+ cell lines, there was a difference in their susceptibilities to the anti- 
CD30 RITs. It may be possible that these different cell lines express different levels of 
CD30, and this may play a role in how susceptible they are to RITs. This idea was explored 
in earlier studies, but surprisingly no relation between the CD30 expression and 
susceptibility to anti-CD30 RITs was found (35). There other factors that play a role in how 
susceptible a given cell line may be to RITs. Some of these factors include the differences 
in internalization of the surface antigen (usually a receptor) and differences in how the toxin 
is processed once inside the cell. These other factors may explain the differences in the 
susceptibility of these cell lines. 
Since the long-term objective is to develop an anti-CD30 therapeutic agent for 
clinical trials, future directions would involve further characterizing and development of the 
RIT(s) with the best specific activity. Future studies would include in vitro stability assays, 
pharmacokinetics (T1/2) studies, and toxicity (LD50) studies. In addition, the anti-tumor 
activity in a mouse subcutaneous tumor model will be measured. The RIT(s) with the most 
favorable properties can still be improved in several ways. Although the candidate RIT 
would already have high activity towards CD30, it is still possible to make a more active RIT 
by increasing the RIT’s Fv’s affinity through in vitro affinity maturation. While there are a 
number of approaches to affinity maturation (codon-based mutagenesis, CDR walking, error 
prone replication, and synthetic CDR construction), one of the most efficient methods is to 
mutagenize hot spots in the Vh and Vl of CDR3, which play a critical role in antigen 
binding. Using phage display technology, panning of hot spot mutant libraries using CD30+ 
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cells should yield mutants with increased affinity. This strategy has been previously applied 
to other RITs with dramatic increases in affinity, activity and yield (44, 45). In addition, it 
may be possible to decrease the RIT’s non-specific toxicity by lowering the isoelectric point 
(Pi) of the Fv through mutation of exposed surface basic or neutral residues in the framework 
region to acidic residues (identified by molecular modeling). In another RIT, this approach 
resulted in a more than 2 fold decrease in non-specific toxicity in mice (46). While these 
earlier strategies involve improving the RIT itself, it is also worthwhile to investigate what 
conditions might increase the efficacy of the RIT. Since the antitumor effects of a RIT are 
affected by how many antigen binding sites are present on the tumor cell, agents (such as 
interferon gamma or IL-4) which may upregulate the expression of CD30 in malignant cells 
should be examined in in vitro cytotoxicity assays and in animal tumor models. Furthermore, 
previous studies with other RITs have demonstrated that chemotherapy can sensitize 
malignant cells to RITs (Pastan, unpublished data). Flence, animal tumor studies could be 
performed by pretreating animals with chemotherapy before applying the RIT. These 
combinations of strategies should optimize the candidate RIT(s) to have the greatest clinical 
efficacy. 
If one of these novel anti-CD30 dsFv RITs is selected for clinical trials, it is important 
to consider how to incorporate it into a therapeutic regimen. RITs would be especially 
helpful in dealing with cancer cells that are chemotherapy resistant or in eliminating minimal 
residual disease. Another RIT developed in the Pastan lab (BL22) has been found to 
eliminate minimal residual disease in patients with chemotherapy resistant Hairy Cell 
Leukemia (24). Previous studies with anti-CD30 MAbs reveal that these antibodies do reach 
the tumor in most cases. Hence, RITs, which are smaller than IgG’s, should be able to reach 
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tumor sites. Since chemotherapy has also been found to sensitize cancer cells to RITs, it 
would perhaps be most effective to include the anti-CD30 dsFv RITs with the typical 
chemotherapy regimen for HD or ALCL. By adding RITs to the chemotherapy regimen, the 
RITs may be able to eliminate chemotherapy resistant cells and minimal residual disease as 
well as decrease the doses of chemotherapy drugs needed, hence reducing the co-morbidities 
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Fv of MAb 
translocation toxin moiety 
domain 
Figure la. Diagram of a disulfide-stabilized recombinant immunotoxin (dsFv RIT). Note 
that V, is covalently bonded to VH by a disulfide bond. VH is fused to a modified 
Pseduomonas exotoxin (PE-38, 38 in size of the modified toxin in kDa). A Pseudomonas 
exotoxin typically has three domains: 1. a binding domain, 2. a translocation domain, 3. 
toxin moiety. In the RIT, the binding domain is replaced with the Fv of a MAb that targets 
a surface tumor antigen. 
lb. A three dimensional molecular model of a dsFv RIT. (created by the Molecular 
Modeling Section of the Laboratory of Molecular Biology, NCI, NIH) 















T420 y2b 1.9 I shed 
T427 y2a 0.9 III shed 
T105 yl 4.2 II non-shed 
T405 y2b 5.7 VI non-shed 
Affinity measurements and epitope characterization done by Satoshi Nagata of the Pastan Lab, unpublished data) 
Figure 2. Proposed topographical map of CD30 epitope groups determined by mutual 
competition assay (data not shown, done by Satoshi Nagata of the Pastan lab). There are 
six major epitope groups, each labeled with a Roman numeral. Note that T105 and T405 
bind to epitopes that are in the non-shedding portion of CD30. T420 and T427 both bind 
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Figure 3a. A diagram of V, (variable domain of the light chain) and Vn (variable region of the 
heavy chain)cDNA with cysteine mutations introduced and restriction sites added to the 5’ 
and y end (to allow integration into the expression vector). A cysteine mutation was 
engineered in position 100 (framework region 4) for V, and in position 44 (framework 
region 2) for Vn. (FR = framework region, CDR = complementary determining region). The 
cysteine mutations allow Vj to form a disulfide bond with VH during the refolding process. 
3b. Expression plasmid with PE-38 under a T7 promoter used for RIT production. 
3c. Expression vector for VH. Note that VH is fused to a modified Pseudomonas exotoxin (PE-38). 
3d. Expression vector for V, . 

Table 2: Yields of the four anti-CD30 dsFv RITs. Minimal acceptable yield is 1%. A 
yield of 5% or greater is desirable. 
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Figure 4. The four anti-CD30 dsFv RITs analyzed on SDS-Page gel (to confirm size 
and determine purity). 4a. T420 dsFv RIT is shown in a non-reducing gel. The protein 
shown is of correct size (~61 kDa) and is very pure. 4b. T427 dsFv RIT is shown here in 
non-reducing and reducing conditions. Reducing conditions cleaves the disulfide bond, 
separating VH-PE38 from VL. 4c. T105 dsFv is shown in both non-reducing and reducing 
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Figure 5. In vitro Cytotoxicity assays of anti-CD30 dsFv RITs in A431/CD30 cells (a & b) 
and in Atac4 (CD30-) cells (c & d). The final concentration of the RIT in the media (ng/ml) 
is plotted against the counts per minute (CPM) of 3H-Leucine (which correlates with cell 
count). The red bar indicates where the counts are 50% of the starting value and identify the 
IC50 point. 
5a. T105, T420, & T6 in A431/CD30 cells 
5b. T105, T405, T427, & T6 in A431/CD30 cells 
5c. T105, T420, T6 in Atac4 cells 
5d. T105, T405, T427 in Atac4 cells. 

a Karpas 299 cells 
b Karpas 299 cells 
c. SUDHL-1 Cells d. SUDHL 1 Cells 
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Figure 6. In vitro cytoxicity assays of anti- 
CD30 RITs in Karpas 299 (ALCL), SUDHL-1 
(ALCL), and L540 (HD). The final cone, of 
RITs in media is plotted against counts per 
minute of 3H-Leucine. The red bar indicate 
where the counts are at 50% of the starting 
value and identify the IC50 point. 
6a. T105, T420, & T6 in Karpas 299 
6b. T105, 1427, T405, & T6 in Karpas 299 
6c. T105, T420, T6 in SUDHL-1 
6d. T105, T427, T405, & T6 in SUDHL-1 
6e. T105, T420 & T6 in L540 
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Table 4 (a & b): Summary of cytotoxicity studies of the anti-CD30 dsFv RIT in a 
number of different cell lines. IC50 values of the RIT in each cell line is listed. 









A431/CD30 2.05 ng/ml > 100 ng/ml 1.05 ng/ml 2 ng/ml 
Karpas 299 41 ng/ml > 100 ng/ml 22 ng/ml >30 ng/ml 
(~40ng/ml?) 
SUDHL-1 13 ng/ml > 100 ng/ml 8 ng/ml 11 ng/ml 
Atac 4 
(neg. control) 
310 ng/ml 710 ng/ml 720 ng/ml not 
included 
b. 








400 ng/ml 700 ng/ml 480 ng/ml 
240 ng/ml 640 ng/ml 300 ng/ml 
A431/CD30 1.5 ng/ml 0.63 ng/ml 0.7 ng/ml 
1.9 ng/ml 0.73 ng/ml 0.8 ng/ml 
Karpas 299 
(ALCL) 
53 ng/ml 17 ng/ml 20 ng/ml 
60ng/ml 19ng/lm 24ng/ml 
SUDHL-1 
(ALCL) 
18 ng/ml 8 ng/ml 9.8 ng/ml 
19 ng/ml 7.4 ng/ml 11 ng/ml 
L540 (HD) 105 ng/ml 60 ng/ml 90 ng/ml 

Table 5: Surface Plasmon Resonance Assay Results. The k()n and koff rates were measured 
BIAcore biosensor, and the Kd for each anti-CD30 dsFv RIT was calculated. 
Anti-CD30 
dsFv RIT 
kon (1/MS) k0ff(l/s) Kd (M) 




T420 5.3 x 104 3.0 x 10 3 5.8 x 10 8 1.9x10 9 
T427 5.9 x 104 2.1 x 10 3 3.6 x 10 8 0.9 x 10 9 
T105 6.1 x 104 7.4 x 10 4 1.2 x 10 8 4.2 x 10 9 
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